



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

The New Treatment Fund

**Medicines Recommended by NICE and AWMSG
Health Board Formulary Status
(due on formulary in 2017)**

BACKGROUND

The Welsh Government launched the New Treatment Fund in January 2017. The fund provides an additional £16 million annually for health boards and trusts in Wales to support the faster introduction of new medicines recommended by the National Institute for Health and Care Excellence (NICE) and the All Wales Medicines Strategy Group (AWMSG).

The New Treatment Fund requires the seven health boards and one NHS trust to make recommended medicines available as soon as is reasonably practicable and certainly within 60 days of the publication of the decision. For NICE recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For AWMSG recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60 day timescale may be delayed because a Commercial Access Agreement (CAA) has not yet been agreed. In such circumstances this is indicated within the report. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

In April 2017 the Welsh Government issued revised directions for health boards and NHS trusts, with an accompanying Welsh Health Circular, *The New Treatment Fund – Access to medicines recommended by NICE and AWMSG* (WHC [2017] 001).

A health board formulary is an official list of medicines which may be prescribed within the health board to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All medicines listed in this report were recommended in 2017 and due to be on formulary no later than 31 December 2017.

SOURCE OF INFORMATION

Across Wales, six of the seven health boards use the online “Inform” formulary software programme provided and maintained by the NHS Wales Informatics Service (NWIS). Abertawe Bro Morgannwg University Health Board (UHB) and Velindre NHS Trust (Velindre Cancer Centre) have separate formulary systems. Velindre NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This report has been compiled through a combination of an analysis of health board formularies and the submission of data and additional information from Chief Pharmacists.

Table 1. Formulary status and time elapsed since latest AWMSG/NICE recommendation for New Treatment Fund medicines (as of 10 November 2017)

Appraisal Approval Date*	CAA Available Date [†]	AWMSG or NICE ref	Medicine name	Abbreviated indication	Health Board formulary status ^{A#}						
					ABMU	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf	Hywel Dda	Powys
11/01/2017		TA427	Pomalidomide	Multiple myeloma			1			30	78
11/01/2017		TA428	Pembrolizumab	Lung cancer (previously treated)	1		1	65	100	27	78
25/01/2017		TA429	Ibrutinib	Leukaemia	1		1	50	51	1	64
25/01/2017		TA430	Sofosbuvir/velpatasvir	Hepatitis C			1		51	1	
25/01/2017		TA431	Mepolizumab	Asthma	1		1	68	51	13	64
07/02/2017		ID758 (HST6)	Asfotase alfa	Hypophosphatasia	0	153	30	0	149	2	156
22/02/2017		HST4	Migalastat	Fabry disease	0	40	30	0	43	135	140
22/02/2017		TA432	Everolimus	Renal cancer		0	1				69
22/02/2017		TA433	Apremilast	Psoriatic arthritis			1		23	20	
02/03/2017		ID785 (TA443)	Obeticholic acid	Biliary cirrhosis	56		64	117	57	20	53
02/03/2017		ID794 (TA439)	Cetuximab	Colorectal cancer	20	1				55	53
02/03/2017		ID794 (TA439)	Panitumumab	Colorectal cancer	27		1	50	50	55	53
10/03/2017		ID904 (TA442)	Ixekizumab	Psoriasis	1		56	91	49	12	45
14/03/2017		1586	Aflibercept (Eylea®)	Myopic choroidal neovascularisation	1		0			1	49
14/03/2017		1658	Triptorelin	Prostate cancer			1		38	1	
15/03/2017		ID827 (TA441)	Daclizumab	Multiple sclerosis	42		1			7	
03/04/2017		2597	Idelalisib	Follicular lymphoma	1		0			29	29
13/04/2017		ID579 (TA445)	Secukinumab	Psoriatic arthritis	11		1		19	19	11
13/04/2017		ID579 (TA445)	Certolizumab pegol	Psoriatic arthritis			1			19	
27/04/2017		ID843 (TA456)	Ustekinumab	Crohn's disease	1	7	34		40	43	7
27/04/2017		ID804 (TA450)	Blinatumomab	Leukaemia					40	43	7
28/04/2017		ID722 (TA446)	Brentuximab	Hodgkin lymphoma						4	42
28/04/2017		ID671 (TA451)	Ponatinib	Leukaemia						42	6
12/05/2017		ID858 (TA449)	Sunitinib	Neuroendocrine tumours		0			0	28	28
12/05/2017		ID858 (TA449)	Everolimus	Neuroendocrine tumours		0	19		0	28	28
19/05/2017		ID908 (TA448)	Etelcalcetide	Hyperparathyroidism	1	5	12	46	18	49	21
31/05/2017		ID709 (HST5)	Eliglustat	Gaucher disease	0	40	37	0	6	37	37
31/05/2017	28/07/2017	ID990 (TA447)	Pembrolizumab	Lung cancer (previously untreated)	60	10	37	64	1		10
02/06/2017		ID763 (TA460)	Adalimumab	Uveitis		19	18		28	19	
02/06/2017		ID763 (TA460)	Dexamethasone	Uveitis		14			28	19	
02/06/2017		ID972 (TA462)	Nivolumab	Hodgkin lymphoma	0	6	18		28	19	1
09/06/2017		ID837	Pirfenidone	Idiopathic pulmonary fibrosis		3	11			12	
09/06/2017		ID934 (TA457)	Carfilzomib	Multiple myeloma	4	10	10	41	14	12	1
09/06/2017	23/06/2017	ID959 (TA465)	Olaratumab	Sarcoma	25	3	11	24	4	12	1
09/06/2017		ID854 (TA455)	Etanercept	Plaque psoriasis		33	11			12	
09/06/2017		ID854 (TA455)	Ustekinumab	Plaque psoriasis		33	11			12	
09/06/2017		ID854 (TA455)	Adalimumab	Plaque psoriasis		33	11			12	
15/06/2017	19/06/2017	ID1013 (TA458)	Trastuzumab emtansine	Breast cancer	6	4	11	18	6	6	1

Appraisal Approval Date*	CAA Available Date*	AWMSG or NICE ref	Medicine name	Abbreviated indication	Health Board formulary status ^{A#}						
					ABMU	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf	Hywel Dda	Powys
22/06/2017		ID984 (TA461)	Roflumilast	Chronic obstructive pulmonary disease	0	7	2	56	5	8	1
22/06/2017		ID621 (TA459)	Collagenase clostridium histolyticum	Dupuytren's contracture		7					1
29/06/2017		ID979 (TA466)	Baricitinib	Rheumatoid arthritis	5	1	5	50	2	8	1
07/07/2017		ID899 (TA467)	Holoclax	Eye burns	40	31	6	48	7	45	42
10/07/2017		ID931 (TA463)	Cabozantinib	Renal cancer	0	2	1		0	31	
10/07/2017		ID782 (TA464)	Alendronic acid (oral)	Osteoporosis		0	33				
10/07/2017		ID782 (TA464)	Ibandronic acid (oral)	Osteoporosis		0	33				
10/07/2017		ID782 (TA464)	Risedronate sodium (oral)	Osteoporosis		0	33				
10/07/2017		ID782 (TA464)	Ibandronic acid (IV)	Osteoporosis		0	8				
10/07/2017		ID782 (TA464)	Zoledronic acid (IV)	Osteoporosis		0	33				
12/07/2017		3435	Aviptadil phenolamine	Erectile dysfunction	0	6	14	36	6	31	37
20/07/2017		ID872 (TA479)	Reslizumab	Asthma	16	11	12	28	8	50	29
26/07/2017		ID841 (TA472)	Obinutuzumab	Follicular lymphoma	14	16	4	23	2	26	23
27/07/2017		ID870 (TA471)	Eluxadoline	Irritable bowel syndrome	0	11	4	22	22	20	22
04/08/2017		ID776 (TA475)	Dimethyl fumarate	Psoriasis		7	4	20	14	13	13
04/08/2017		ID1058 (TA476)	Paclitaxel albumin-bound nanoparticles	Pancreatic cancer		0	4		0		13
07/08/2017		3371	Adalimumab	Acne inversa		4	4		11	10	
07/08/2017		2224	Cefuroxime	Eye inflammation		4	11	46			11
07/08/2017		2527	Triamcinolone hexacetonide	Juvenile idiopathic arthritis		4	1	46	11	10	11
08/08/2017		ID1016 (TA473)	Cetuximab	Head and neck cancer	0	3	3		10	1	
10/08/2017		ID1012 (TA474)	Sorafenib	Liver cancer	0	0	3		0		8
24/08/2017		ID512 (TA478)	Brentuximab vedotin	Lymphoma	0	7	7				15
07/09/2017		ID456 (TA481) , ID346 (TA482)	Basiliximab	Kidney transplant		0	27				
07/09/2017		ID456 (TA481) , ID346 (TA482)	Tacrolimus (immediate release)	Kidney transplant		0	27				
07/09/2017		ID456 (TA481) , ID346 (TA482)	Mycophenolate mofetil	Kidney transplant		0	27				
08/09/2017		ID526 (TA480)	Tofacitinib	Rheumatoid arthritis	0	3	26	41	17	47	28
20/09/2017	09/10/2017	ID900 (TA484)	Nivolumab	Lung cancer (non-squamous)	46	0	13		19	16	
20/09/2017	09/10/2017	ID811 (TA483)	Nivolumab	Lung cancer (squamous)	46	0	13		19	16	
22/09/2017		ID952 (TA486)	Aflibercept	Myopic choroidal neovascularisation		0	10		0		
22/09/2017	04/10/2017	ID994 (TA845)	Sarilumab	Rheumatoid arthritis	12	5	10	37	12	20	14
28/09/2017	27/10/2017	ID884	Ibrutinib	Waldenstrom's macroglobinaemia	0	4	5		29	8	
5/10/2017	27/10/2017	ID944	Venetoclax	Leukaemia	22	7	4		22	14	12
10/10/2017		2680	Ivacaftor	Cystic fibrosis	0	27	24		3	31	
12/10/2017		ID1056	Regorafenib	Gastrointestinal stromal tumours (sarcoma)		14			1		27

Appraisal Approval Date*	CAA Available Date†	AWMSG or NICE ref	Medicine name	Abbreviated indication	Health Board formulary status^#						
					ABMU	Aneurin Bevan	BCU	Cardiff and Vale	Cwm Taf	Hywel Dda	Powys
13/10/2017		ID971	Nivolumab	Head and neck cancer (squamous)	22	5	21	28	5	28	
17/10/2017		3282	Desmopressin	Nocturia	0	8	17	24	22	24	
19/10/2017		3372	5-aminolaevulinic acid	Skin cancer		6	17			22	26
19/10/2017		3295	C1 inhibitor	Angioedema	0	6	17				
19/10/2017		3373	Dolutegravir	HIV		6	17			22	20
19/10/2017		3007	Glecaprevir/pibrentasvir	Hepatitis C		29	22	22	20	22	20
19/10/2017		976	Lenvatinib	Thyroid cancer	0	6	17	22	20	22	
19/10/2017		3436	Tiotropium	Asthma		4	17				20

* Time to formulary addition from appraisal approval date should be within two months for AWMSG Health Technology Appraisals (including the orphan and ultra-orphan appraisal process), NICE Health Technology Appraisals and HSTs and cancer drugs. For NICE recommendations these should be following the first publication of the FAD or the FED for HSTs, and for AWMSG approvals following Welsh Government ratification.

^ Number of days from latest AWMSG/NICE approval statements and formulary status are data submitted by health board/trust. Where no number is provided this can generally be assumed to indicate that the medicine is "already on formulary" but for a different indication. However this is not always the case.

The determination of formulary status is considered as the availability of the medicine to treat patients.






† CAA (Commercial Access Agreement) Available Date information is provided by the all Wales Medicines Procurement Specialist Pharmacist

Table 2. Velindre Cancer Centre medicines status

Appraisal Approval Date*	CAA Available Date	AWMSG or NICE ref	Medicine name	Abbreviated indication	Health Board formulary status ^{A#}					
					C+V DOF	Powys* DOF	ABMU*	Cwm Taf DOF	ABUHB DOF	VCC ONLY DOF
11/01/2017		TA428	Pembrolizumab 2 nd line	Lung cancer	**	100	100	100	100	100
22/02/2017		TA432	Everolimus	Renal cancer						
02/03/2017		ID794	Cetuximab	Colorectal cancer						
02/03/2017		ID794	Panitumumab	Colorectal cancer	50	50	50	50	50	50
14/03/2017		1658	Triptorelin	Prostate cancer	38	38	38	38	38	38
12/05/2017		ID858	Everolimus	Neuroendocrine tumours		0	0	0	0	0
12/05/2017		ID858	Sunitinib	Neuroendocrine tumours	0	0	0	0	0	0
31/05/2017**		ID990	Pembrolizumab 1 st line	Lung cancer	**	1	1	1	1	1
09/06/2017		ID959	Olaratumab	Sarcoma	4	4	4	4	4	4
15/06/2017		ID1013	Trastuzumab Emtansine	Breast	6	6	6	6	6	6
10/07/2017		ID931 (TA463)	Cabozantinib	Renal cancer	0	0	0	0	0	0
04/08/2017		ID1058	Paclitaxel albumin-bound nanoparticles	Pancreatic cancer	0	0	0	0	0	0
08/08/2017		ID1016	Cetuximab	Head and neck cancer	10	10	10	10	10	10
10/08/2017		ID1012	Sorafenib	Liver cancer	0	0	0	0	0	0
20/09/2017		ID900	Nivolumab	Lung cancer (non-squamous)	**	0	0	0	0	0
20/09/2017		ID811	Nivolumab	Lung cancer (squamous)	**	0	0	0	0	0
13/10/2017		ID971	Nivolumab	Head and neck cancer (squamous)	0	0	0	0	0	0
19/10/2017		976	Lenvatinib	Thyroid cancer						

*Powys and Abertawe Bro Morgannwg also commission cancer services from other cancer providers. These dates relate to the Powys and Abertawe Bro Morgannwg populations that Velindre Cancer Centre is commissioned for and there may be variability with dates from other cancer service providers.

** Cardiff and Vale UHB have their own lung service.

Key		On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition.
		On formulary. However the number of days stated is outside of the 60 day timescale.
		Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 10 November 2017
		Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 10 November 2017
		Start of 60 day timescale delayed due to lack of financial/PAS agreement. Stated number is the number of days from financial/PAS agreement to formulary addition. Where no number is stated this indicates the medicine is currently not on formulary.